E1	Procedure:T1 Name:T83
E2	Or:T2 Arg:E1 Arg2:E3
E3	Procedure:T3 Name:T46
E4	Eq-Comparison:T4 Operator:T47 Value:T48
E5	Condition:T5 Name:T49 Minimum-Count:E4
E6	Eq-Comparison:T6 Temporal-Period:T50
E7	Procedure:T7 Temporality:E6
E8	Eq-Comparison:T8 Temporal-Period:T51
E10	Drug:T10 Name:T53 Temporality:E8
E11	Drug:T11 Name:T54
E12	Modifier:T12 Modifies:T53
E14	Drug:T14 Name:T55
E15	Drug:T15 Name:T56
E16	Modifier:T16 Modifies:T55
E18	Drug:T18 Name:T60
E19	Modifier:T19
E20	Or:T20 Arg:E18 Arg2:E21
E21	Drug:T21 Name:T62
E22	Drug:T22 Name:T63
E24	Study:T24
E25	Eq-Comparison:T25 Temporal-Period:T65
E26	Procedure:T26 Name:T66 Temporality:E25
E27	Procedure:T27 Name:T67
E28	Or:T28 Arg:E27 Arg2:E30
E29	Other:T29 Is-Other:E30
E30	Procedure:T30
E31	Eq-Comparison:T31 Temporal-Period:T69
E32	Condition:T32 Name:T70 Temporality:E31
E33	Or:T33 Arg:E32 Arg2:E35
E34	Eq-Comparison:T34 Temporal-Period:T71
E35	Condition:T35 Name:T72 Temporality:E34
E36	Risk:T36 Polarity:T73 Risk-For:E37
E37	Condition:T37 Name:T74
E38	Condition:T38 Name:T75 Temporality:E39
E39	Eq-Comparison:T39 Operator:T76 Value:T77 Temporal-Unit:T78
E40	Condition:T40 Name:T79
E41	Condition:T41 Name:T80
E42	Or:T42 Arg:E41 Arg2:E43
E43	Condition:T43 Name:T81
E44	Condition:T44 Name:T82
E46	Negation:T84 Negates:E7
E47	Modifier:T85 Modifies:E7
E48	Modifier:T86 Modifies:T49
E49	And:T87 Arg:E5 Arg2:E46
E9	Drug:T9 Name:T58
E13	Modifier:T13 Modifies:T62
E17	Condition:T17 Name:T68
E23	Modifier:T23 Modifies:T68
E50	Modifier:T52 Modifies:T75
E51	Modifier:T57 Modifies:T80
E52	Modifier:T59 Modifies:T79
E53	Modifier:T61 Modifies:T81
E54	And:T64 Arg:E43 Arg2:E44
T1	Procedure 38 55	histopathological
T2	Or 56 58	or
T3	Procedure 59 82	cytological examination
T4	Eq-Comparison 136 148	at least one
T5	Condition 159 165	lesion
T6	Eq-Comparison 215 223	received
T7	Procedure 230 239	treatment
T8	Eq-Comparison 278 297	previously received
T10	Drug 298 330	anti-programmed death receptor-1
T11	Drug 332 336	PD-1
T12	Modifier 338 346	antibody
T14	Drug 348 378	anti-programmed death ligand-1
T15	Drug 380 385	PD-L1
T16	Modifier 387 395	antibody
T18	Drug 429 434	PD-L2
T19	Modifier 436 444	antibody
T20	Or 445 447	or
T21	Drug 448 496	anti-cytotoxic T lymphocyte-associated antigen-4
T22	Drug 498 504	CTLA-4
T24	Study 576 581	study
T25	Eq-Comparison 601 620	previously received
T26	Procedure 625 629	TACE
T27	Procedure 631 654	radiofrequency ablation
T28	Or 655 658	and
T29	Other 659 664	other
T30	Procedure 678 688	treatments
T31	Eq-Comparison 711 718	history
T32	Condition 722 746	gastroesophageal varices
T33	Or 747 749	or
T34	Eq-Comparison 750 756	active
T35	Condition 757 770	cardia ulcers
T36	Risk 794 798	risk
T37	Condition 802 810	bleeding
T38	Condition 858 868	hemorrhage
T39	Eq-Comparison 869 882	within 1 year
T40	Condition 926 929	HCC
T41	Condition 943 946	HCC
T42	Or 947 949	or
T43	Condition 956 974	cholangiocarcinoma
T44	Condition 979 982	HCC
T46	Procedure-Name 59 82	cytological examination
T47	Eq-Operator 136 144	at least
T48	Eq-Value 145 148	one
T49	Condition-Name 159 165	lesion
T50	Eq-Temporal-Period 215 223	received
T51	Eq-Temporal-Period 278 297	previously received
T53	Drug-Name 298 330	anti-programmed death receptor-1
T54	Drug-Name 332 336	PD-1
T55	Drug-Name 348 378	anti-programmed death ligand-1
T56	Drug-Name 380 385	PD-L1
T58	Drug-Name 397 427	anti-programmed death ligand-2
T60	Drug-Name 429 434	PD-L2
T62	Drug-Name 448 496	anti-cytotoxic T lymphocyte-associated antigen-4
T63	Drug-Name 498 504	CTLA-4
T65	Eq-Temporal-Period 601 620	previously received
T66	Procedure-Name 625 629	TACE
T67	Procedure-Name 631 654	radiofrequency ablation
T68	Condition-Name 671 677	cancer
T69	Eq-Temporal-Period 711 718	history
T70	Condition-Name 722 746	gastroesophageal varices
T71	Eq-Temporal-Period 750 756	active
T72	Condition-Name 757 770	cardia ulcers
T73	Polarity 789 793	high
T74	Condition-Name 802 810	bleeding
T75	Condition-Name 858 868	hemorrhage
T76	Eq-Operator 869 875	within
T77	Eq-Value 876 877	1
T78	Eq-Temporal-Unit 878 882	year
T79	Condition-Name 926 929	HCC
T80	Condition-Name 943 946	HCC
T81	Condition-Name 956 974	cholangiocarcinoma
T82	Condition-Name 979 982	HCC
T83	Procedure-Name 38 55	histopathological
T84	Negation 211 214	not
T85	Modifier 224 229	local
T86	Modifier 149 158	evaluable
T87	And 203 206	and
T9	Drug 397 427	anti-programmed death ligand-2
T13	Modifier 506 516	antibodies
T17	Condition 671 677	cancer
T23	Modifier 665 670	liver
T52	Modifier 835 857	upper gastrointestinal
T57	Modifier 931 942	sarcomatoid
T59	Modifier 912 925	fibrous layer
T61	Modifier 950 955	mixed
T64	And 975 978	and
A1	Eq-Operator-Value T47 GTEQ
A2	Eq-Temporal-Period-Value T50 past
A3	Eq-Temporal-Period-Value T51 past
A9	Eq-Temporal-Period-Value T65 past
A10	Eq-Temporal-Period-Value T69 past
A11	Eq-Temporal-Period-Value T71 present
A12	Polarity-Value T73 high
A13	Eq-Operator-Value T76 LTEQ
A14	Eq-Temporal-Unit-Value T78 year
R1	Abbrev-Of Arg1:E11 Arg2:E10
R2	Abbrev-Of Arg1:E15 Arg2:E14
R3	Abbrev-Of Arg1:E18 Arg2:E9
R4	Abbrev-Of Arg1:E19 Arg2:E9
R5	Abbrev-Of Arg1:E22 Arg2:E21
R6	Treatment-For Arg1:E30 Arg2:E17
R7	Caused-By Arg1:E36 Arg2:E35